MDM2 and prostate cancer: Applying the dominant model for the minor allele (MDM2 SNP55TT + TC versus CC), no significant effect on risk was found for lung- (OR = 1.04; 95% CI = 0.91–1.19), breast (OR = 1.01; 95% CI = 0.88–1.16), or prostate cancer (OR = 1.05; 95% CI = 0.92–1.19; Table 1; Fig. 3).